To specify the priority of the obligations of the United States Government if the debt ceiling is reached, to provide for an emergency appropriation of funds to pay for certain defense and national security obligations during a gap in funding, and for other purposes.

Intellectual Property and Process Patent Issues- HR 1908, Patent Reform Act (all provisions).

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Reform H.R. 1908, Import Safety Act H.R. 2100 Affordable Health Choices Act Patent Settlements H.R. 1432 S 316 Generic Biologics S 1685 H.R. 5629 Physician Payment Sunshine Act S 2029

Client expense: Not reported · Firm income: $98,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100 Affodable Health Choices Act

Client expense: Not reported · Firm income: $105,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Intellectual Property and Process Patent Issues--HR 1908, Patent Reform Act; implementation of PL 108-173, matters related to Medicare and Medicaid coverage and reimbursement; issues relating to Precription Drug User Fee Act and ASP+6; issue related to follow-on biologics; issues related to FDA repeal of Avastin; issues related to coverage of Luncentis and Avastin, HR 942 - American Research and Competitiveness Act of 2011.

Client expense: Not reported · Firm income: Not reported

Intellectual Property and Process Patent Issues--HR 1908, Patent Reform Act; implementation of PL 108-173, matters related to Medicare and Medicaid coverage and reimbursement; issues relating to Precription Drug User Fee Act and ASP+6; issue related to follow-on biologics; issues related to FDA repeal of Avastin; issues related to coverage of Luncentis and Avastin, HR 942 - American Research and Competitiveness Act of 2011.

Client expense: Not reported · Firm income: Not reported

Intellectual Property and Process Patent Issues HR 1908, Patent Reform Act (all provisions).

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Reform H.R. 1908, Import Safety Act H.R. 2100 Affordable Health Choices Act Patent Settlements H.R. 1432 S 316 Generic Biologics S 1685 H.R. 5629 Physician Payment Sunshine Act S 2029

Client expense: Not reported · Firm income: $98,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100 Affodable Health Choices Act

Client expense: Not reported · Firm income: $105,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100 Affodable Health Choices Act

Client expense: Not reported · Firm income: $105,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Reform H.R. 1908, Import Safety Act H.R. 2100 Affordable Health Choices Act Patent Settlements H.R. 1432 S 316 Generic Biologics S 1685 H.R. 5629 Physician Payment Sunshine Act S 2029

Client expense: Not reported · Firm income: $98,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Intellectual Property and Process Patent Issues. HR 1908, Patent Reform Act (all provisions).

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Intellectual Property and Process Patent Issues. HR 1908, Patent Reform Act (all provisions).

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Reform H.R. 1908, Import Safety Act H.R. 2100 Affordable Health Choices Act Patent Settlements H.R. 1432 S 316 Generic Biologics S 1685 H.R. 5629 Physician Payment Sunshine Act S 2029

Client expense: Not reported · Firm income: $98,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100 Affodable Health Choices Act

Client expense: Not reported · Firm income: $105,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Intellectual Property and Process Patent Issues. HR 1908, Patent Reform Act (all provisions).

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1, Full-year Continuing Appropriations Act, 2011: NIH, NSF, NIST, and Office of Science (Department of Energy); student financial aid including Pell Grants and SEOG; funding for the Department of Education's International Studies Centers (Title VI of HEOA); funding for VA health care, prosthetic research, VA research facilities, and veterans' educational benefits; (cont. next page) HR 1, continued: and research funding for the National Endowment for the Humanities and the National Endowment for the Arts. HR 1363, Further Additional Continuing Appropriations Amendments, 2011: funding for the University of Pittsburgh Drug Discovery Institute; Center for Vaccine Research/Regional Biocontainment Laboratory; Center of Excellence in Biomedical Informatics; Army, Navy, and Air Force Centers for Injury Prevention and Performance Enhancement; and DoD research funding (6.1, 6.2, and 6.3). HR 1473, Department of Defense and Full-Year Continuing Appropriations Act, 2011: funding for the University of Pittsburgh Drug Discovery Institute; Center for Vaccine Research/Regional Biocontainment Laboratory; Center of Excellence in Biomedical Informatics; Army, Navy, and Air Force Centers for Injury Prevention and Performance Enhancement; and DoD research funding (6.1, 6.2, and 6.3). HR 1908, Prioritization of the obligations of the U.S. government: emergency appropriations of funds and prioritization of obligations, if the debt ceiling is reached. HR 2219, FY2012 Department of Defense Appropriations Act: funding for the University of Pittsburgh Drug Discovery Institute; Center for Vaccine Research/Regional Biocontainment Laboratory; Center of Excellence in Biomedical Informatics; Army, Navy, and Air Force Centers for Injury Prevention and Performance Enhancement; and DoD research funding (6.1, 6.2, and 6.3). HR 2017, Continuing Appropriations Act, 2012: NIH, NSF, NIST, and Office of Science (Department of Energy); student financial aid including Pell Grants and SEOG; funding for the Department of Education's International Studies Centers (Title VI of HEOA); funding for VA health care, prosthetic research, VA research facilities, and veterans' educational benefits; and research funding for the National Endowment for the Humanities and the National Endowment for the Arts. HR 2055, FY2012 Military Construction and Veterans Affairs Appropriations Act: funding for VA health care, prosthetic research, VA research facilities, and veterans' educational benefits. HR 2354, FY2012 Energy and Water Appropriations Act: research funding for the Office of Science at the Department of Energy, super-computing, and fossil energy. HR 2560, Cut, Cap, and Balance Act of 2011: preservation of research and student financial aid funding. HR 2584, FY2012 Department of the Interior, Environment Appropriations Act: research funding for the National Endowment for the Humanities and the National Endowment for the Arts. HR 2605, Protect Spending Priorities Act: preservation of research and student financial aid funding. S. 365, Budget Control Act of 2011: preservation of health care, education, research and student financial aid funding. Draft House bill (no number), S 1599, FY2012 Labor/Health and Human Services/Education Appropriations Act: funding for NIH research, international studies programs (Title VI, HEOA), and student financial aid.

Patent Reform H.R. 1908, Import Safety Act H.R. 2100 Affordable Health Choices Act Patent Settlements H.R. 1432 S 316 Generic Biologics S 1685 H.R. 5629 Physician Payment Sunshine Act S 2029

Client expense: Not reported · Firm income: $98,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100 Affodable Health Choices Act

Client expense: Not reported · Firm income: $105,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Reform H.R. 1908, Import Safety Act H.R. 2100 Affordable Health Choices Act Patent Settlements H.R. 1432 S 316 Generic Biologics S 1685 H.R. 5629 Physician Payment Sunshine Act S 2029

Client expense: Not reported · Firm income: $98,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100 Affodable Health Choices Act

Client expense: Not reported · Firm income: $105,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1, Full-Year Continuing Appropriations Act, 2011: NIH, NSF, NIST, and Office of Science research funding; student financial aid including Pell Grants and SEOG; funding for the Department of Education's International Studies Centers (Title VI of HEOA); funding for VA health care, prosthetic research, VA research facilities, and veterans' educational benefits; (continued on next page) HR 1, continued: and research funding for the National Endowment for the Humanities and the National Endowment for the Arts. HR 1363, Further Additional Continuing Appropriations Amendments, 2011: funding for the University of Pittsburgh Drug Discovery Institute (Center for Orphan Disease Drug Discovery); Center for Vaccine Research/Regional Biocontainment Laboratory; Center of Excellence in Biomedical Informatics; Army, Navy, and Air Force Centers for Injury Prevention and Performance Enhancement; and DoD research funding (6.1, 6.2, and 6.3). HR 1473, Department of Defense and Full-Year Continuing Appropriations Act, 2011: funding for the University of Pittsburgh Drug Discovery Institute (Center for Orphan Disease Drug Discovery); Center for Vaccine Research/Regional Biocontainment Laboratory; Center of Excellence in Biomedical Informatics; Army, Navy, and Air Force Centers for Injury Prevention and performance Enhancement; and DoD research funding (6.1, 6.2, and 6.3). HR 1908, Prioritization of the obligations of the U.S. government: emergency appropriations of funds and prioritization of obligations, if the debt ceiling is reached. HR 2219, FY2012 Department of Defense Appropriations Act: funding for the University of Pittsburgh Drug Discovery Institute (Center for Orphan Disease Drug Discovery); Center for Vaccine Research/Regional Biocontainment Laboratory; Center of Excellence in Biomedical Informatics; Army, Navy, and Air Force Centers for Injury Prevention and Performance Enhancement; and DoD research funding (6.1, 6.2, and 6.3).

Intellectual Property and Process Patent Issues; HR 1908, Patent Reform Act (all provisions); S.23 - Patent Reform Act; General Patent Reform Issues; Specfic issues lobbied (bill numbers): Patent reform legislation

Client expense: $1,140,295 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Intellectual Property and Process Patent Issues; HR 1908, Patent Reform Act (all provisions).

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1432 - Patent Settlements; H.R. 1695 - Generic Biologics; H.R. 5629 - Physician Payment Sunshine Act; S.2029 - Patent Reform; H.R. 1908 - Import Safety Act; H.R. 3100 - Affordable Health Choices Act S.515 - Patent Reform Act Financial services and general appropriations bill - 2010 S.A. 4727 - The Middle Class Tax Cut Act 2010

Client expense: Not reported · Firm income: $50,000

Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE

Intellectual Property and Process Patent Issues; HR 1908, Patent Reform Act (all provisions).

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Reform H.R. 1908, Import Safety Act H.R. 2100 Affordable Health Choices Act Patent Settlements H.R. 1432 S 316 Generic Biologics S 1685 H.R. 5629 Physician Payment Sunshine Act S 2029

Client expense: Not reported · Firm income: $98,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100 Affodable Health Choices Act

Client expense: Not reported · Firm income: $105,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE